Professionals from the Hereditary Cancer Genetics Group at Vall d’Hebron Institute of Oncology (VHIO), led by Dr. Judith Balmaña, participated…
NOTICIAS
The funds have supported projects at the Vall d’Hebron Research Institute (VHIR) and the Vall d’Hebron Institute of Oncology (VHIO)…
On June 8, the FERO Gala brought together researchers, physicians, companies, philanthropists, and representatives of civil society in Barcelona who…
Professionals from the Vall d’Hebron Institute of Oncology (VHIO) and Vall d’Hebron University Hospital actively participated in the 2026 Annual…
Eva Muñoz-Couselo from VHIO has participated in two studies that reinforce the potential of oncolytic immunotherapies as a new therapeutic…
Results from the phase 3 TALAPRO-3 trial show that the combination of enzalutamide and talazoparib reduces the risk of progression…
The HERIZON-GEA-01 open-label, phase 3 clinical trial was designed to compare first-line treatment with the bispecific antibody zanidatamab plus chemotherapy…
Researchers at VHIO have published an article in the journal European Journal of Cancer on the evolution of targeted therapies…
Themed Driving progress through disruptive science and clinical innovation in oncology, VHIO’s Scientific Report 2025 highlights some of the many…
Pharmaceutical company Gilead held the award ceremony for the 11th and 12th editions of the Gilead Biomedical Research Grants this…
